Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PTG-100 · 1 trial · 1 indication
Percentage change from baseline to Week 6 in villous height-to crypt depth (Vh:Cd) ratio
| Arm | Type | Description |
|---|---|---|
| PTG-100 | EXPERIMENTAL | Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days. |
| Placebo | PLACEBO_COMPARATOR | Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days. |
| Name | Type | Description |
|---|---|---|
| PTG-100 | DRUG | PTG-100, 600mg taken twice daily in capsule form for 42 days |
| Placebo | DRUG | Placebo taken twice daily in capsule form for 42 days |
Inclusion Criteria: * Diagnosis of celiac disease Exclusion Criteria: * Active GI disease or history of clinically significant diseases * Diagnosis of Crohn's disease or ulcerative colitis.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | Amlitelimab |
| Forte Biosciences Inc. | FBRX | 1 | PHASE2 | FB102 |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 1 | PHASE2 | TEV-53408 |
| Barinthus Biotherapeutics plc Sponsored ADR | BRNS | 1 | EARLY_PHASE1 | VTP-1000 |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
PTG-100 is an investigational small molecule being developed for the treatment of celiac disease, a gastrointestinal condition. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
PTG-100 is a small molecule designed to target the underlying mechanisms of celiac disease. However, the specific molecular target has not been disclosed in available information.
PTG-100 is being developed by Protagonist Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol PTGX.
PTG-100 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. A Phase 1 trial has been completed.
PTG-100 has one completed Phase 1 clinical trial, identified as NCT04524221, which evaluated the drug in patients with celiac disease. The trial enrolled 12 participants in the United States.
No alternative names for PTG-100 have been disclosed. It is referred to solely as PTG-100 in available clinical trial information.